Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Ryan Stuchbery, Natalie J Kurganovs, Patrick J Mccoy, Colleen C Nelson, Vanessa M Hayes, Niall M Corcoran, Christopher M Hovens
CURRENT CANCER DRUG TARGETS | BENTHAM SCIENCE PUBL LTD | Published : 2015
Cancer is fundamentally a genomic disease caused by mutations or rearrangements in the DNA or epigenetic machinery of a patient. An emerging field in cancer treatment targets key aberrations arising from the mutational landscape of an individual patient's disease rather than employing a cancer-wide cytotoxic therapy approach. In prostate cancer in particular, where there is an observed variation in response to standard treatments between patients with disease of a similar pathological stage and grade, mutationdirected treatment may grow to be a viable tool for clinicians to tailor more effective treatments. This review will describe a number of mutations across multiple forms of cancer that ..View full abstract
Related Projects (2)
Investigation of the source of new testosterone production in prostate tumours that become resistant to existing hormonal (testosterone lowering and blocking) therapies
Prostate cancer is critically dependent upon continued testosterone stimulation, even when the disease becomes resistant to existing hormona..
Awarded by NHMRC
This work is supported by NHMRC project grants 1024081 (N.M.C., J.S.P., A.J.C. and C.M.H.) and 1047581 (C.M.H., G.M., I.H., J.S.P., A.J.C., N.M.C.), as well as a federal grant from the Australian Department of Health and Aging to the Epworth Prostate Cancer Centre, Epworth Hospital (A.J.C., N.M.C., C.M.H.) as well as to C.C.Nelson and V.M. Hayes. N.M. Corcoran is supported by a David Bickart Clinician Research Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne. N.J Kurganovs is supported by a scholarship from Australian Prostate Cancer Research.